Hatchtech head lice drug to be commercialised by Dr Reddy's
15 September, 2015Dr Reddy's Laboratories has signed a commercialisation agreement with Melbourne-based company Hatchtech, the developer of prescription head lice product Xeglyze Lotion.
Orthocell data validated for bone generation
15 September, 2015Shares in Orthocell have jumped over 15%, following the presentation of successful 'cell factory' data at the 34th Annual Meeting of the European Bone and Joint Infection Society.
Yabao and UniSA collaborate on drug discovery laboratory
10 September, 2015Yabao Pharmaceutical and the University of South Australia will collaborate on the development of new cancer treatments through a co-funded drug discovery laboratory, to be led by UniSA Professor Shudong Wang.
ReCell proposal rated highly in the US
02 September, 2015Avita Medical's cell suspension preparation device was this week the subject of two pieces of news: a patent validation in 11 European countries and a proposal to utilise the technology in a US disaster preparedness program.
Refining respiratory disease diagnosis via smartphone
01 September, 2015ResApp Health has enrolled its first patient at Princess Margaret Hospital, Perth, for a study which is designed to optimise and validate the company's machine-learning algorithms.
R&D grant to accelerate Parkinson's treatment
31 August, 2015Living Cell Technologies will receive a Callaghan Innovation R&D Growth Grant totalling an estimated NZ$2 million, which will reimburse the company for 20% of eligible New Zealand research and development expenditure over the next three years.
Adherium opens on ASX
27 August, 2015Digital health company Adherium has listed on the Australian Securities Exchange for the first time, opening yesterday at $0.55 per share.
DibbsBarker appoints life science and healthcare expert
26 August, 2015Law firm DibbsBarker has announced the appointment of Andrew Rankine as a new special counsel in the company's Sydney office.
Advancing Australia's cell therapy
21 August, 2015A strategic cooperation agreement between CTM CRC, GE Healthcare Australia and HealthInSA outlines a long-term partnership focused on advancing Australia's cell therapy industry.
Linkage grant to improve diagnostic imaging
21 August, 2015Clarity Pharmaceuticals and the University of Melbourne have been awarded an ARC Linkage grant to fund the development of new agents for diagnostic imaging using PET. The ultimate aim of the project is to try to improve molecular imaging of the brain for various disorders.
Paradigm Biopharmaceuticals lists on ASX, announces clinical trial
20 August, 2015Drug developer Paradigm Biopharmaceuticals has listed on the Australian Securities Exchange for the first time.
ROI slipping in biomedical research
18 August, 2015The increasing amount of money spent on biomedical research in the US over the past 50 years has resulted in diminished return on investment in terms of life-expectancy gains and new drug approvals, according to researchers from the Johns Hopkins Bloomberg School of Public Health.
IDT generic drug products to be commercialised in the US
12 August, 2015US-based company ANI Pharmaceuticals has agreed to market and distribute up to 18 generic pharmaceutical products which have recently been acquired by IDT Australia.
Stem cell trial for knee osteoarthritis underway
10 August, 2015 by Lauren DavisRegeneus shares jumped over 20% as the regenerative medicine company announced the first patient to be treated by Progenza, its mesenchymal stem cell therapy treatment for knee osteoarthritis.
Research collaboration to treat pulmonary fibrosis
07 August, 2015Pharmaxis and Synairgen will develop a selective inhibitor to the LOXL2 enzyme to treat the lung disease idiopathic pulmonary fibrosis — a fatal condition that causes persistent and progressive scarring of the alveoli in the lungs.
